Moderna (MRNA)
(Delayed Data from NSDQ)
$122.11 USD
+1.71 (1.42%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $121.66 -0.45 (-0.37%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$122.11 USD
+1.71 (1.42%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $121.66 -0.45 (-0.37%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Zacks News
Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?
by Zacks Equity Research
With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.
Moderna (MRNA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Moderna (MRNA) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 5.73% and 18.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Moderna (MRNA) Ahead of Earnings?
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $120.65, marking a -1% move from the previous day.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs.
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.
Moderna (MRNA) Stock Moves -0.32%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $124.77 in the latest trading session, marking a -0.32% move from the prior day.
Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment, recovery in surgical procedures and new product launches are likely to have pushed sales growth.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $126.62, marking a +0.56% move from the previous day.
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.
Company News for Jul 7, 2023
by Zacks Equity Research
Companies in The News Are: JBLU, AAL, F, MRNA, GENI.
Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine
by Zacks Equity Research
Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
by Zacks Equity Research
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $123.54, moving +1.49% from the previous trading session.
Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab
by Zacks Equity Research
Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $123 in the latest trading session, marking a +1.93% move from the prior day.
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.